Pregnancy support- Vitamin Treatment
Linolleic Acid -
updated: 03 November 2008
Calcium and conjugated linoleic acid reduces pregnancy-induced hypertension and decreases intracellular calcium in lymphocytes
Am J Hypertens. 2006 Apr;19(4):381-7
Herrera JA, Arévalo-Herrera M, Shahabuddin AK, Ersheng G, Herrera S, Garcia RG, López-Jaramillo P.
BACKGROUND: The aim of the present study was to determine whether the beneficial effect of oral supplementation with calcium and conjugated linoleic acid (CLA) in the reduction of the incidence of pregnancy-induced hypertension (PIH) is related with changes in plasma levels of prostanoids, renin, angiotensin II, calciotropic hormones, and plasma and intracellular ionized free calcium. METHODS: These mediators were determined using the blood samples obtained from a randomized, double-blind, placebo-controlled trial that included 48 healthy primigravidas with a family history of preeclampsia and with diastolic notch, recruited from four outpatient clinics from two developing countries. Participants were randomized to daily oral doses of elemental calcium and CLA or lactose-starch placebo from week 18 to week 22 of gestation until delivery. RESULTS: The incidence of PIH was significantly reduced in women receiving the supplement (2 women [8.3%]) compared with placebo (10 women [41.7%]) (relative risk = 0.20, 95% confidence interval 0.05-0.82, P = .01). There were no significant differences in the plasma concentrations of ionized calcium, prostaglandin E(2), renin, angiotensin II, parathormone,and calcitonine. The concentration of intracellular ionized free calcium presented a significant reduction after interventions (92.0 nmol/L [range 62.5 to 220 nmol/L] v 62.5 nmol/L [range 28 to 200 nmol/L; P = .01) in the supplemented group but not in the placebo group. The women who developed PIH (n = 12) presented a significant increase in the concentrations of intracellular calcium after interventions (120 nmol/L [range 89.2 to 240 nmol/L] v 137.5 nmol/L [range 89.2 to 138 nmol/L; P = .02). CONCLUSIONS: Calcium and CLA supplementation during pregnancy reduces the incidence of PIH, and decreases the intracellular concentration of ionized free calcium in peripheral blood lymphocytes.
Publication Types:
- randomized, double-blind, placebo-controlled trial
Online - Article
Calcium plus linoleic acid therapy for pregnancy-induced hypertension
Int J Gynaecol Obstet. 2005 Dec;91(3):221-7. Epub 2005 Oct 21
Herrera JA, Shahabuddin AK, Ersheng G, Wei Y, Garcia RG, López-Jaramillo P.
OBJECTIVE: To determine the effect of dietary supplementation of calcium plus conjugated linoleic acid (calcium-CLA) in reducing the incidence of vascular endothelial dysfunction in pregnant women at high risk of developing pregnancy-induced hypertension (PIH). PATIENTS AND METHODS: This randomized, double-blind, placebo-controlled trial conducted at 4 outpatient clinics in 2 developing countries recruited 48 healthy primigravidas younger than 19 years or older than 35 years who had a family history of pre-eclampsia and diastolic notch. Twenty-four participants received daily elemental calcium (600 mg) plus CLA (450 mg) and 24 received placebo from week 18 to 22 of pregnancy until delivery. RESULTS: Calcium-CLA supplementation reduced significantly the incidence of PIH (2 cases [8%] in the study group vs. 10 cases [42%] in the placebo group; relative risk, 0.20; 95% confidence interval, 0.05-0.82; P=.01). Endothelial dysfunction was also significantly reduced after calcium-CLA supplementation (in 18 women [75%] vs. 4 women [17%]; P<.001), compared with the placebo group (in 15 [63%] vs. 9 women [38%]; P=.08). CONCLUSION: In pregnant women at high risk for PIH, calcium-CLA supplementation decreases the incidence of PIH and improves endothelial function.
Publication Types:
- randomized, double-blind, placebo-controlled trial
Online - Abstract
Prevention of preeclampsia by linoleic acid and calcium supplementation: a randomized controlled trial
Herrera JA, Arevalo-Herrera M, Herrera S.
OBJECTIVE: To determine the effect of low doses of linoleic acid and calcium on prostaglandin (PG) levels and the efficacy of this treatment in the prevention of preeclampsia. METHODS: In a randomized, double-blind, placebo-controlled study we treated 86 primigravidas with risk factors for preeclampsia (high biopsychosocial risk [above 3 points], positive roll-over test, and high mean blood pressure [above 85 mmHg)] with daily doses of either 450 mg linoleic acid and 600 mg calcium (n=43) or 450 mg starch and 600 mg lactose placebo (n=43) during the third trimester of pregnancy. RESULTS: Four women in the experimental group (9.3%) developed preeclampsia compared with 16 (37.2%) controls (relative risk 0.25, 95% confidence interval 0.09, 0.69, P < .001). The median serum levels of PGE2 after 4 weeks of treatment increased by 106% in the experimental group (P=.03) and decreased by 33% in the control group (P=.02). The median ratio between thromboxane B2 and PGE2 decreased by 40% in the experimental group (P=.02) and increased by 18% in the control group (P=.14). No significant differences were observed in the median ratio between thromboxane B2 and 6-keto PGF1alpha in either group. No serious maternal or neonatal side effects of treatment occurred in either group. CONCLUSION: The administration of low daily doses of linoleic acid and calcium during the third trimester of pregnancy reduced the incidence of preeclampsia significantly in women at high risk, possibly by correcting the PGE2 levels.
Publication Types:
- randomized, double-blind, placebo-controlled study
Online - Abstract
Publication Types:
|
